Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

With the relatively rapid development of the COVID-19 pandemic, vaccine development has
become crucial for limiting disease transmission. The accelerated growth in the approved …

Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …

Background There are limited data on the effectiveness of the vaccines against symptomatic
coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect …

Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including …

Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel …

Abstract BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …

The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the
importance of addressing whether the total CD4+ and CD8+ T cell recognition is also …

Background Information is limited regarding the effectiveness of the two-dose messenger
RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in …

Background Despite the high efficacy of the BNT162b2 messenger RNA vaccine against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough …